Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement.

• SureNano Science initiated an FDA-aligned IND-enabling GLP toxicology and pharmacology program for lead candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioned within the growing GLP-1 therapeutic market as a minnow among giants.
• The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, GEP-44 preclinical results position it head-to-head with leaders such as Ozempic, Mounjaro, Wegovy.
• The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes.
• The company is also exploring acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments.
• SureNano’s transition toward a pharmaceutical-focused model follows its acquisition of GlucaPharm, now operating in the rapidly expanding GLP market expected to hit $200 billion in sales by 2030.

SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, has begun a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The company is initiating a Good Laboratory Practice (“GLP”) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (“FDA”) requirements, intended to support an Investigational New Drug (“IND”) application and represents a necessary step before first-in-human clinical trials. Against a backdrop of a rapidly expanding GLP market, SureNano is positioning itself as an agile entrant in the next-generation GLP-1 landscape having developed a patented high-performing second-generation incretin-based therapy after securing licensing rights to the GEP-44 compound developed by Syracuse University.

The GLP economic opportunity is substantial with the global GLP-1 receptor agonist market projections range from $100 billion to J.P. Morgan estimates of the broader incretin market to reach $200 billion by 2030, with ~25 million by 2030 patients using GLP-1 therapies in the United States alone. SureNano is…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to SURNF are available in the company’s newsroom at https://ibn.fm/SURNF

Forward-Looking Information

Forward-looking information involves numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking information. These risks and uncertainties include, among other items: market prices, study and trial results, continued availability of capital and financing, and general economic, market, or business conditions. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. The Company cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what the Company currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include: expectations regarding the size of the markets the company operates in; the ability of the Company to successfully achieve its business objectives; plans for growth, political, social and environmental uncertainties; presence of laws and regulations which may impose restrictions in the markets where the Company operates; market volatility; fluctuations in investor sentiment; changes in the Company’s business plans; and trial and study results. Accordingly, readers should not place undue reliance on forward-looking information and statements. Readers are cautioned that reliance on such information and statements may not be appropriate for other purposes. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. The Company does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.

Prospective Investors Should Consult with their Advisors.

The information contained in this presentation does not purport to be all-inclusive or to contain all information that a prospective investor may require. Prospective investors are encouraged to conduct their own analysis and reviews of the Corporation and of the information contained in this presentation. Without limitation, prospective investors should consider the advice of their financial, legal, accounting, tax and other advisors and such other factors they consider appropriate in investigating and analyzing the Corporation. All amounts are expressed in Canadian dollars unless otherwise noted. The Canadian Securities Exchange (CSE) has not reviewed and does not accept responsibility for the adequacy or the accuracy of the contents of this release or promotional content.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Austin, Texas
www.InvestorWire.com
512.354.7000 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

This contant was orignally distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44.